ジョンソン・エンド・ジョンソンがシーズ・ホールディングスの買収を完了

AsiaNet 77113 （0092）

【ニューブランズウィック（米ニュージャージー州）2019年1月17日PR Newswire＝共同通信JBN】

＊買収でJ&Jの科学ベースのダーマコスメティック美容製品のポートフォリオが拡大

ジョンソン・エンド・ジョンソン（Johnson & Johnson 、NYSE: JNJ）は17日、株式会社シーズ・ホールディングス（Ci:z Holdings Co., Ltd. 、TYO: 4924、同社）に対する総額約2300億円の買収を完了したと発表した。買収は同社の公開株を１株5900円で全額現金による買い取りを含む一連の取引を通じて終えた。ジョンソン・エンド・ジョンソンは公開買い付けに応じなかった残りの同社株について、日本の法律の下での株式併合によって2019年前半に取得し、同社の東京証券取引所の上場を廃止する適切な行動を取る計画。

Logo - https://mma.prnewswire.com/media/403394/Johnson_and_Johnson_Logo.jpg

スキンケア製品ラインの「ドクターシーラボ（Dr.Ci:Labo）」や「ラボラボ（Labo Labo）」、「ジェノマー（Genomer）」を販売する同社は今後、ジョンソン・エンド・ジョンソンのコンシューマー企業グループ傘下に入る。

ジョンソン・エンド・ジョンソン・コンシューマー（Johnson & Johnson Consumer）のワールドワイド会長であるホルヘ・メスキタ氏は「ドクターシーラボとラボラボ、ジェノマーの取得で、われわれの拡大する化粧品の品ぞろえは、ユニークなダーマコスメティック・イノベーションを伴って強化される。この重要な取引の完了をとてもうれしく思い、世界中の健康と美容の消費者に、効能があって、科学に基づくスキンケア製品を届けられるのを楽しみにしている」と述べた。

この買収に伴う1株利益への影響は、ジョンソン・エンド・ジョンソンが2018年第4四半期決算の記者発表に合わせて公表する2019年のガイダンスで触れられる。

▽ジョンソン・エンド・ジョンソン（Johnson & Johnson）について

ジョンソン・エンド・ジョンソンは、良好な健康が活力のある人生、地域社会の繁栄、将来の発展の基盤であると信じる。だからこそ、同社は130年以上もの間、あらゆる年代、あらゆる人生段階の人々の健康を支えようと努めてきた。今日、世界最大級で広範な拠点を有するヘルスケア企業としての強みを最大限に生かし、世界中の誰もが、どこにいても、心身の健康と健全な環境を享受することができるよう、同社は適正な価格でヘルスケアにアクセスできる、より健全な社会の実現に向けて努力している。同社は、その思いと科学、創意工夫を1つにして、人類のために健康の流れを根本から変えようとしている。

ソース：Johnson & Johnson

▽メディア問い合わせ先

Ernie Knewitz

+1 (732) 524-6623, +1 (917) 697-2318

(M), eknewitz@its.jnj.com

Mel Tyndale-Biscoe

+65 8798 2475 (Singapore)

MTYNDALE@its.jnj.com

Donna Lorenson

+1 (410) 258-8571

dlorens@its.jnj.com

▽投資家問い合わせ先

Lisa Romanko

+1 (732) 524-2034

LRomank3@its.jnj.com

Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd.

PR77113

NEW BRUNSWICK, New Jersey, Jan. 17, 2019 /PRNewswire=KYODO JBN/ --

--Acquisition Expands J&J's Portfolio of Science-based Dermocosmetic Beauty

Products

Johnson & Johnson (NYSE:JNJ) today announced the completion of the acquisition

of Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company") for a total purchase

price of approximately JPY 230 billion. The acquisition was completed through a

series of transactions that included an all-cash tender offer to acquire

publicly held shares of the Company for JPY 5,900 per share.  Johnson & Johnson

plans to acquire the remaining shares of the Company that were not tendered in

the tender offer through a share consolidation under Japanese law during the

first half of 2019 and take appropriate actions to delist the Company from the

Tokyo Stock Exchange.

Logo - https://mma.prnewswire.com/media/403394/Johnson_and_Johnson_Logo.jpg

The Company, which markets the DR. CI:LABO, LABO LABO and GENOMER line of

skincare products, will now become part of the Johnson & Johnson Family of

Consumer Companies.

"The addition of DR. CI:LABO, LABO LABO and GENOMER to our franchise

strengthens our growing beauty portfolio with unique dermocosmetic innovation,"

said Jorge Mesquita, Worldwide Chairman, Johnson & Johnson Consumer. "We are

very pleased to complete this important transaction and look forward to

bringing efficacious, science-backed skincare products to our health and beauty

consumers around the world."

Any EPS impact of the transaction will be included in the 2019 guidance

provided on Johnson & Johnson's Q4 2018 earnings call.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant

lives, thriving communities and forward progress. That's why for more than 130

years, we have aimed to keep people well at every age and every stage of life.

Today, as the world's largest and most broadly-based health care company, we

are committed to using our reach and size for good. We strive to improve access

and affordability, create healthier communities, and put a healthy mind, body

and environment within reach of everyone, everywhere. We are blending our

heart, science and ingenuity to profoundly change the trajectory of health for

humanity.

NOTE CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the

Private Securities Litigation Reform Act of 1995 regarding the potential

transaction between Johnson & Johnson and the Company. The reader is cautioned

not to rely on these forward-looking statements. These statements are based on

current expectations of future events. If underlying assumptions prove

inaccurate or known or unknown risks or uncertainties materialize, actual

results could vary materially from the expectations and projections of Johnson

& Johnson and the Company. Risks and uncertainties include, but are not limited

to: the satisfaction of closing conditions for the transaction, including the

receipt of regulatory approvals for the transaction; the tender of the

requisite amount of the outstanding shares of the Company; the possibility that

the transaction will not be completed in the expected timeframe or at all; the

potential that the expected benefits and opportunities of the transaction, if

completed, may not be realized or may take longer to realize than expected;

uncertainty of commercial success for new and existing products; manufacturing

difficulties and delays; economic conditions, including currency exchange and

interest rate fluctuations; competition, including technological advances, new

products and patents attained by competitors; changes to applicable laws and

regulations, including tax laws and domestic and foreign health care reforms;

adverse litigation or government action; changes in behavior and spending

patterns or financial distress of purchasers of health care products and

services; and trends toward health care cost containment. In addition, if and

when the transaction is consummated, there will be risks and uncertainties

related to the ability of the Johnson & Johnson Family of Companies to

successfully integrate the products, employees and operations of the Company,

as well as the ability to ensure continued performance or market growth of the

Company's products. A further list and description of these risks,

uncertainties and other factors can be found in Johnson & Johnson's publicly

available filings with the U.S. Securities and Exchange Commission. Copies of

these filings, as well as subsequent filings, are available online at

www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson &

Johnson does not undertake to update any forward-looking statement as a result

of new information or future events or developments.

SOURCE: Johnson & Johnson

CONTACT: Media Contacts: Ernie Knewitz, +1 (732) 524-6623, +1 (917) 697-2318

(M), eknewitz@its.jnj.com; Mel Tyndale-Biscoe, +65 8798 2475 (Singapore),

MTYNDALE@its.jnj.com; Donna Lorenson, +1 (410) 258-8571, dlorens@its.jnj.com;

Investor Contact: Lisa Romanko, +1 (732) 524-2034, LRomank3@its.jnj.com